AmCad BioMed Statistics

Total Valuation

AmCad BioMed has a market cap or net worth of TWD 848.66 million. The enterprise value is 588.89 million.

Market Cap	848.66M
Enterprise Value	588.89M

Important Dates

The next estimated earnings date is Friday, May 9, 2025.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 8.42% in one year.

Current Share Class	n/a
Shares Outstanding	63.33M
Shares Change (YoY)	+8.42%
Shares Change (QoQ)	+4.20%
Owned by Insiders (%)	6.60%
Owned by Institutions (%)	n/a
Float	32.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	15.98
PB Ratio	1.28
P/TBV Ratio	1.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.64
EV / Sales	11.09
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.79

Financial Position

The company has a current ratio of 16.63, with a Debt / Equity ratio of 0.02.

Current Ratio	16.63
Quick Ratio	15.37
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.20
Interest Coverage	-359.24

Financial Efficiency

Return on equity (ROE) is -9.26% and return on invested capital (ROIC) is -6.93%.

Return on Equity (ROE)	-9.26%
Return on Assets (ROA)	-6.69%
Return on Invested Capital (ROIC)	-6.93%
Return on Capital Employed (ROCE)	-9.66%
Revenue Per Employee	1.56M
Profits Per Employee	-1.49M
Employee Count	34
Asset Turnover	0.09
Inventory Turnover	0.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.80% in the last 52 weeks. The beta is 0.52, so AmCad BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	-51.80%
50-Day Moving Average	17.55
200-Day Moving Average	21.30
Relative Strength Index (RSI)	30.05
Average Volume (20 Days)	59,242

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AmCad BioMed had revenue of TWD 53.11 million and -50.58 million in losses. Loss per share was -0.88.

Revenue	53.11M
Gross Profit	32.93M
Operating Income	-64.66M
Pretax Income	-52.88M
Net Income	-50.58M
EBITDA	-51.94M
EBIT	-64.66M
Loss Per Share	-0.88

Full Income Statement

Balance Sheet

The company has 365.71 million in cash and 10.87 million in debt, giving a net cash position of 354.84 million or 5.60 per share.

Cash & Cash Equivalents	365.71M
Total Debt	10.87M
Net Cash	354.84M
Net Cash Per Share	5.60
Equity (Book Value)	663.72M
Book Value Per Share	8.98
Working Capital	392.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -51.85 million and capital expenditures -2.72 million, giving a free cash flow of -54.57 million.

Operating Cash Flow	-51.85M
Capital Expenditures	-2.72M
Free Cash Flow	-54.57M
FCF Per Share	-0.86

Full Cash Flow Statement

Margins

Gross margin is 62.02%, with operating and profit margins of -121.77% and -95.24%.

Gross Margin	62.02%
Operating Margin	-121.77%
Pretax Margin	-99.57%
Profit Margin	-95.24%
EBITDA Margin	-97.81%
EBIT Margin	-121.77%
FCF Margin	n/a

Dividends & Yields

AmCad BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.42%
Shareholder Yield	-8.42%
Earnings Yield	-5.96%
FCF Yield	-6.43%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AmCad BioMed has an Altman Z-Score of 28.11.

Altman Z-Score	28.11
Piotroski F-Score	n/a